MBOT icon

Microbot Medical

0.9745 USD
+0.0010
0.10%
At close Dec 20, 4:00 PM EST
After hours
1.02
+0.0455
4.67%
1 day
0.10%
5 days
-2.55%
1 month
5.92%
3 months
10.61%
6 months
-4.46%
Year to date
-26.73%
1 year
-28.35%
5 years
-82.90%
10 years
-99.93%
 

About: Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.

Employees: 22

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.47% less ownership

Funds ownership: 6.8% [Q2] → 6.33% (-0.47%) [Q3]

16% less capital invested

Capital invested by funds: $1.11M [Q2] → $933K (-$175K) [Q3]

29% less funds holding

Funds holding: 35 [Q2] → 25 (-10) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Research analyst outlook

We haven’t received any recent analyst ratings for MBOT.

Financial journalist opinion

Positive
Zacks Investment Research
1 week ago
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Neutral
GlobeNewsWire
1 week ago
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Positive
Zacks Investment Research
2 months ago
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
Neutral
GlobeNewsWire
2 months ago
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial.
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
Neutral
GlobeNewsWire
2 months ago
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY®.
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Neutral
GlobeNewsWire
3 months ago
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Positive
Zacks Investment Research
3 months ago
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Neutral
GlobeNewsWire
3 months ago
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
Positive
Zacks Investment Research
4 months ago
Microbot Medical (MBOT) Gets Quality Certification for its System
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.
Microbot Medical (MBOT) Gets Quality Certification for its System
Neutral
GlobeNewsWire
4 months ago
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company's robust quality system The ISO 13485 certification is a validation of the Company's robust quality system
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
Charts implemented using Lightweight Charts™